Tweet
New Xiidra drops from Shire are supposed to be rolled out in the next few months. Based on the news release it looks like it supposed to decrease inflammation by affecting T-Cells ( kind of like Restasis, but I assume it's a different mechanism). I don't have any idea what thecost will be, but here's to hoping it can help some of us.
http://www.medscape.com/viewarticle/866015
Here is a portion of the news release:
The inflammation associated with dry eye is thought to be primarily mediated by T-cells and associated cytokines. One effect of this process may be increased expression of intracellular adhesion molecule-1 (ICAM-1); ICAM 1 may be overexpressed in corneal and conjunctival tissues in dry eye disease. Lifitegrast is a small-molecule integrin antagonist that binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein found on leukocytes, and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule‑1 (ICAM‑1). LFA‑1/ICAM‑1 interaction can contribute to the formation of an immunological synapse resulting in T‑cell activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit T‑cell adhesion to ICAM‑1 in a human T-cell line and may inhibit secretion of inflammatory mediators (cytokines) in human peripheral blood mononuclear cells. The exact mechanism of action of lifitegrast in dry eye disease is not known.
What is Xiidra
Xiidra is a prescription eye drop used to treat the signs and symptoms of dry eye disease.
Important Safety Information
The most common side effects of Xiidra include eye irritation, discomfort or blurred vision when the drops are applied to the eyes, and an unusual taste sensation (dysgeusia). To help avoid eye injury or contamination of the solution, do not touch the container tip to your eye or any surface. If you wear contact lenses, remove them before using Xiidra and wait for at least 15 minutes before placing them back in your eyes.
It is not known if Xiidra is safe and effective in children under 17 years of age.
For additional information, click the link below for full Prescribing Information including Patient Information and discuss with your doctor
www.shirecontent.com/PI/PDFS/XIIDRA_USA_ENG.pdf
http://www.medscape.com/viewarticle/866015
Here is a portion of the news release:
The inflammation associated with dry eye is thought to be primarily mediated by T-cells and associated cytokines. One effect of this process may be increased expression of intracellular adhesion molecule-1 (ICAM-1); ICAM 1 may be overexpressed in corneal and conjunctival tissues in dry eye disease. Lifitegrast is a small-molecule integrin antagonist that binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein found on leukocytes, and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule‑1 (ICAM‑1). LFA‑1/ICAM‑1 interaction can contribute to the formation of an immunological synapse resulting in T‑cell activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit T‑cell adhesion to ICAM‑1 in a human T-cell line and may inhibit secretion of inflammatory mediators (cytokines) in human peripheral blood mononuclear cells. The exact mechanism of action of lifitegrast in dry eye disease is not known.
What is Xiidra
Xiidra is a prescription eye drop used to treat the signs and symptoms of dry eye disease.
Important Safety Information
The most common side effects of Xiidra include eye irritation, discomfort or blurred vision when the drops are applied to the eyes, and an unusual taste sensation (dysgeusia). To help avoid eye injury or contamination of the solution, do not touch the container tip to your eye or any surface. If you wear contact lenses, remove them before using Xiidra and wait for at least 15 minutes before placing them back in your eyes.
It is not known if Xiidra is safe and effective in children under 17 years of age.
For additional information, click the link below for full Prescribing Information including Patient Information and discuss with your doctor
www.shirecontent.com/PI/PDFS/XIIDRA_USA_ENG.pdf
Comment